OXY-1: The Pharmacogenetics of Oxycodone Analgesia in Postoperative Pain

• Status: Completed
• Trial end date: 2007-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Patients undergoing surgery (thyroidectomy and hysterectomy) will postoperatively receive oxycodone intravenously (IV) as pain management with morphine as an escape medicine, if there is insufficient pain relief with oxycodone. Patients' pain and side effects will be registered and after 24 hours they will answer a questionnaire. All included patients will be genotyped accordingly to CYP2D6 and relevant single nucleotide polymorphisms (SNPs), and measures of plasma levels of oxycodone will be performed.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Odense University Hospital
• Treatments: Oxycodone

Criteria

Inclusion Criteria:

• Ages 18-80 years old

• Caucasian race

• Signed informed consent

• Patients admitted for one of the following operations: thyroidectomy, mastectomy, hysterectomy, mammaexpander operation, nasal septum correction and jaw operations.

Exclusion Criteria:

• Allergy towards oxycodone

• Previous daily opioid use

• Known severe illness (terminal cancer, severe dementia, uncompensated heart failure, kidney failure, liver failure and severe lung failure)

• Lack of ability to use patient controlled analgesia or to follow the trial protocol

• Pregnancy

• Severe psychiatric illness

• Alcoholism

• Ongoing treatment with potent CYP2D6 inhibitors (fluoxetine, paroxetine and terbinafine)

• Severe perioperative complications or re-operation within the first 24 hours

• Use of extra pain management during the anaesthesia with an effect after the operation